guido_rasi

EMA appoints Guido Rasi as executive director

pharmafile | October 9, 2015 | Appointment | Medical Communications, Sales and Marketing |  EMA, Guido Rasi 

The European Medicines Agency’s (EMA’s) Management Board has nominated Professor Guido Rasi as the Executive Director of the Agency.

The Board selected Professor Rasi from a shortlist of candidates provided by the European Commission.

Professor Rasi has been invited to give a statement to the European Parliament’s Committee on the Environment, Public Health and Food Safety (ENVI) on 13 October 2015. The appointment of the new executive director will only be made after this session.

Following his nomination, Professor Rasi says: “I am honoured to have been nominated as EMA’s executive director and am grateful for the opportunity to continue our efforts to make the Agency fit for the challenges ahead. I am enormously proud of the Agency and its network.

Advertisement

“Looking to the future, we must continue to meet patients’ legitimate expectations for access to new and safe therapeutic options. This requires that the medicines authorisation process not only supports the early stages of research and development, but also strives to make the best possible use of real world data throughout a medicine’s lifecycle.”

Chair of the management board, Professor Sir Kent Woods, comments: “The Management Board is pleased to announce the nomination of Guido Rasi as Executive Director of EMA. The decision of the Management Board is the result of a robust recruitment process over the last months. We look forward to Professor Rasi resuming his leadership of the Agency.”

Deputy executive director Andreas Pott will continue to lead EMA operations and to legally represent the Agency until the new executive director has officially taken up his duties.

Related Content

AstraZeneca’s Trixeo approved in EU for asthma in patients aged 12 and over

AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved by the European Commission as a …

Sobi’s olezarsen recommended for EU approval in severe hypertriglyceridaemia

Sobi’s olezarsen (TRYNGOLZA) has received a positive opinion from the European Medicines Agency’s Committee for …

EMA selects TrialAssure anonymisation platform for clinical trial documents

TrialAssure has announced that its ANONYMIZE platform has been selected by the European Medicines Agency …

The Gateway to Local Adoption Series

Latest content